Jordi Gratacós1, Esteban Daudén2, Juan Gómez-Reino3, José Carlos Moreno4, Miguel Ángel Casado5, Vicente Rodríguez-Valverde6. 1. Servicio de Reumatología, Hospital Parc Taulí, Sabadell, Barcelona, Spain. Electronic address: jgratacosmas@gmail.com. 2. Servicio de Dermatología, Hospital de la Princesa, Madrid, Spain. 3. Servicio de Reumatología, Complexo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain. 4. Servicio de Dermatología, Hospital Reina Sofía, Córdoba, Spain. 5. Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain. 6. Servicio de Reumatología, Hospital Marqués de Valdecilla, Santander, Spain.
Abstract
PURPOSE: To describe the demographic and clinical characteristics, including health-related quality-of-life (HRQL), in patients with psoriatic arthritis (PsA). METHODS: 287 patients from 18 Spanish centres were assessed. PsA severity was measured using the following criteria: (1) Psoriasis Area and Severity Index (PASI score 0-72, from low to high severity); (2) number of swollen and tender joints; and (3) Health Assessment Questionnaire (HAQ score 0-3 from low to high impairment in daily activities). HRQL assessment was performed using the following criteria: (a) EuroQol-5D (EQ-5D scores 1-3, with a higher score representing a worse HRQL), Visual Analogue Scale (VAS score 0-100, with a higher score representing a better HQRL) and (b) Short Form-36 (SF-36 score 0-100, with a higher score representing a better HRQL). RESULTS: 24.7% of patients were treated with infliximab. In the two groups, 55.7% of the patients were male with a mean age of 52.40±12.53 years. The average number of swollen joints was higher in patients not receiving biological therapy than in those receiving treatment (2.98 vs. 1.54). The mean PASI score was 3.73±5.83, and there was no difference between groups. HAQ scores were higher in patients receiving infliximab than in those not receiving treatment (0.93 vs. 0.70). The mean EQ-5D scores in the two groups indicated a poorer status based on pain and inability to perform usual/daily activities. HRQL measured by VAS score mean was 60.41 ± 20.08, and there was no difference between the groups. The domains in the SF-36 suggesting poorer functioning in the two groups were the physical role (50.76 ± 43.43), physical pain (49.35 ± 25.69) and the overall physical component (37.88 ± 10.87). CONCLUSIONS: PsA is associated with an impaired HRQL characterised by physical pain and poorer functioning in daily activities.
PURPOSE: To describe the demographic and clinical characteristics, including health-related quality-of-life (HRQL), in patients with psoriatic arthritis (PsA). METHODS: 287 patients from 18 Spanish centres were assessed. PsA severity was measured using the following criteria: (1) Psoriasis Area and Severity Index (PASI score 0-72, from low to high severity); (2) number of swollen and tender joints; and (3) Health Assessment Questionnaire (HAQ score 0-3 from low to high impairment in daily activities). HRQL assessment was performed using the following criteria: (a) EuroQol-5D (EQ-5D scores 1-3, with a higher score representing a worse HRQL), Visual Analogue Scale (VAS score 0-100, with a higher score representing a better HQRL) and (b) Short Form-36 (SF-36 score 0-100, with a higher score representing a better HRQL). RESULTS: 24.7% of patients were treated with infliximab. In the two groups, 55.7% of the patients were male with a mean age of 52.40±12.53 years. The average number of swollen joints was higher in patients not receiving biological therapy than in those receiving treatment (2.98 vs. 1.54). The mean PASI score was 3.73±5.83, and there was no difference between groups. HAQ scores were higher in patients receiving infliximab than in those not receiving treatment (0.93 vs. 0.70). The mean EQ-5D scores in the two groups indicated a poorer status based on pain and inability to perform usual/daily activities. HRQL measured by VAS score mean was 60.41 ± 20.08, and there was no difference between the groups. The domains in the SF-36 suggesting poorer functioning in the two groups were the physical role (50.76 ± 43.43), physical pain (49.35 ± 25.69) and the overall physical component (37.88 ± 10.87). CONCLUSIONS: PsA is associated with an impaired HRQL characterised by physical pain and poorer functioning in daily activities.
Authors: Iain B McInnes; Philip J Mease; Georg Schett; Bruce Kirkham; Vibeke Strand; Nicole Williams; Todd Fox; Luminita Pricop; Steffen M Jugl; Kunal K Gandhi Journal: Arthritis Res Ther Date: 2018-06-07 Impact factor: 5.156
Authors: Antonio Romero Pérez; Rubén Queiro; Daniel Seoane-Mato; Eduard Graell; Eugenio Chamizo; Lara Chaves Chaparro; Sara Rojas Herrera; Jordi Pons Dolset; Miguel A Polo Ostáriz; Susana Ruiz-Alejos Garrido; Cristina Macía-Villa; Ana Cruz-Valenciano; María L González Gómez; Carlos Sánchez-Piedra; Federico Díaz-González; Sagrario Bustabad-Reyes Journal: PLoS One Date: 2020-06-17 Impact factor: 3.240
Authors: Giorgio L Colombo; Sergio Di Matteo; Chiara Martinotti; Steffen M Jugl; Praveen Gunda; Mariantonietta Naclerio; Giacomo M Bruno Journal: Clinicoecon Outcomes Res Date: 2018-08-30
Authors: Alice Gottlieb; Jordi Gratacos; Ara Dikranian; Astrid van Tubergen; Lara Fallon; Birol Emir; Laraine Aikman; Timothy Smith; Linda Chen Journal: Rheumatol Int Date: 2018-11-13 Impact factor: 2.631